Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agree, need institutional involvement with a worthwhile amount of share ownership that won’t happen on the OTC.
Wish we could uplist without the RS though.
No kidding. From what I read, bad bond investment, considering inflation + 42B worth of customer withdrawals in a panic = SVIB belly up. Rip
Agree! Fair post. Let’s get this bad boy rollin.
Let’s hope! Got at least 1 order set slightly lower than here in the event that it dips further. Kinda waiting to see how our first 1-2 quarters post Lannett goes.
Good luck. Def shouldn’t hold anything that makes ya lose sleep over it. It’s been a long road, here’s to hoping this does pan out in our favor before too much longer.
Same! $ELTP$
The accumulation continues.
$ELTP$
If they are working on all those, that’s some massive upside potential from here. We know Oxy for sure.
$ELTP$
Probably the same reason Adderall ownership hasn’t been 100% moved over yet - may need a cash cushion as internal sales and marketing force gets started / ramped up.
Any kind of sweet spot for generic company acquisitions based on revenues, in your experience? Or is it just too situational?
Iirc, Epic was purchased for $550M when they were at about $100M in revs a year.
Gotta pass the time somehow, you know.
$ELTP$
“Zero room for growth with this company” is the most incorrect thing I’ll read today.
People change jobs for a variety of reasons, almost impossible to tell from the outside looking in without more info.
Would be interested to hear jour’s thoughts on this though.
Hopefully as significant as the Adderalls, or even more so. Only about 1 month left before we start out on our own with sales/marketing!
$ELTP$
I actually agree. R&D spending (and dilution) has gone on for literal decades and the stock is where it is. Buying back, say, 100M shares is roughly $3.5M bucks right now. Or half it, 50M:$1.5M, something.
That *should* change investor sentiment significantly..
That being said, I see the rationale for focusing on sales and marketing at this particular time as we pivot away from Lannett, the uncertainty. But some focused stockholder attention at some point would be welcome.
Agreed. At 3ish cents, hard to see much more downside with a profitable company and continuing pipeline, with higher profit margins on existing drugs likely around the corner.
Same ole same ole. Based on the board, guess we still have some accumulation going on. Smart choice.
$ELTP$
“large capital expenditure that they screwed Epic over to cover etc”
That’s some interesting revisionist history, completely false of course. No one put a gun to Epic’s head and forced them to make a deal with Elite.
I guess all partnerships, investments, etc. that don’t pan out as expected mean one party screwed the other over? Let’s make no mention of the impact of outside regulatory decisions…
Seems feasible.
$ELTP$
No trading today, rip. Zzzzz
Nice post. I agree and I don’t think Elite starting our own sales and marketing force is what would kill it. They’ve survived way worse than that. From no revenues to 30M+ a year and profitable with a continuously growing pipeline.
Doesn’t really matter what anyone’s opinion is of Nasrat or his performance - the fact is that he owns several hundred million shares. If ANYONE stands to benefit from Elite having real success, it’s him by far.
Same. Ready to buy if any more dips present themselves.
I concur with SlipperySailor - Nasrat is expecting a better year even figuring in a dip for the first quarter of next fiscal year. Time for Kirkov to show his sales prowess.
When is the next CC usually? April/May?
This was supposedly the last study before filing yeah? Assuming FDA doesn’t move the goalpost again?
Tax debt as in old NOLs from the past?
Definitely continuing to add this year and will swoop in for more if we see goofy CC games being played. Way more upside potential than downside IMO.
Purdue wouldn’t just file subsequent lawsuits against each newcomer as they submit their ANDAs?
Bingo. A fair evaluation, IMO.
Interested to see what overseas opportunities Kirkov can capitalize on, and also if we can get a generic Oxy on the market.
Also interesting to note that we’ll be selling several products under our own label now. Should be able to squeeze more profit out of all of them, though I expect it will matter most far and away on the Adderall products.
$ELTP$
CEO doesn’t control stock price for the millionth billionth trillionth time.
Snagged more shares today, got some dry powder left in case we see any CC-related shenanigans.
$ELTP$
Agreed.
Not much to say that hasn’t already been said - I think reverse splits get a bad rap because they’re almost always done from weakness, not strength. You see the huge corporations sometimes forward splitting when the price gets too high, and it seems the reverse splits come in when some companies need to try and stay on their exchanges. Furthermore, just because Nasrat has floated the idea of an RS doesn’t necessarily mean he wants to do it - it will still affect him like the rest of us. I do laundry and dishes even though I hate it.
Hopefully if one is done here, it is a uniquely positive outcome due to fundamentals. IMO, upside potential is much greater than downside. Stay the course.
Loxapine launch PR on May 4th, 2021. Not a grand slam product but an additional launch since Adderall nonetheless.
Relatively small pharmaceutical company we’re talking about here and, notably, a pandemic has been in effect during those 3 years which has delayed clinical trials for some pipeline candidates.
“Prasco distributes Loxapine Capsules under their Burel Pharmaceutical label and Loxapine has captured a modest market share **and we are hoping to do better in the future**.”
…
“**The rest of the products will be evaluated on case by case basis and figure out how we can bring them home** or if it’s in our best interest to keep them with a partner.”
Seems like the intent has been there to sell more of our products in-house.
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q2 2023 Earnings Conference Call November 15, 2022 11:30 AM ET
https://seekingalpha.com/article/4558062-elite-pharmaceuticals-inc-eltp-q2-2023-earnings-call-transcript
Do we know that it is/was a 50/50 split with Lannett?
Did you never get an answer to the revenue questions?? Color me shocked. ;)
Ready to hear how the Q went.
$ELTP$
I do wonder how our self marketing strategy will shake out.
It’ll incur $X amount more in overhead to have the sales and marketing division built out and running but we’ll keep Y% more in profit selling it ourselves.
Yes, doing this ahead of Nasrat’s planned timeline but maybe it works out in our favor - maybe Kirkov is a crucial asset that wouldn’t have been available to join Elite had we waited a couple more years. Time will tell.
P.S. Anyone here still buying more or waiting to see how this goes?
Although I’d never bash Elite the company or stock in an attempt to get a cheaper price, I’m admittedly still buying too. ;)
Snagged a few more today myself, got some more limit orders still open slightly below current price.
Let’s go ELTP.